Back

Baseline characteristics of patients with HFrEF on dapagliflozin: final analysis of baseline data from the EVOLUTION-HF DEallEF study HFrEF cohort

30 August 2026 (16:15 - 16:45)
Organised by: Logo
Congress Presentation Part of: Heart failure: diagnosis and therapy Heart Failure with Reduced Ejection Fraction (HFrEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Birgit Assmus

Justus-Liebig University of Giessen, Giessen (Germany)

4 More presentations in this session

Presentation thumbnail
Recovered vs remission heart failure among patients with LVEF improvement in non-Ischaemic HFrEF
Doctor T. Nabeta (Sagamihara, JP)
Abstract
Presentation thumbnail
Real-world barriers to long-term ARNI therapy in HFrEF: a one-year analysis of tolerability and dose achievement
Doctor M. Santos Silva (Aveiro, PT)
Abstract
Presentation thumbnail
GLP-1 receptor agonists added to guideline-directed medical therapy in heart failure with reduced ejection fraction: a propensity score-matched analysis
Doctor I. Chough (Stony Brook, US)
Abstract
Presentation thumbnail
Cardiopulmonary exercise testing following conduction system versus biventricular pacing in heart failure: a substudy of the PhysioSync-HF randomized trial
Doctor A. Silveira (Porto Alegre, BR)
Abstract

Access the full session

Session thumbnail
Heart failure: diagnosis and therapy

The Event

Event poster

ESC Congress 2026

30 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Early treatment of heart failure: a non-interventional observational study programme of patients with heart failure and initiated on dapagliflozin (EVOLUTION HF)
21 May 2023
thumbnail
Congress Presentation
Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58
31 August 2019
thumbnail
Congress Presentation
Baseline characteristics of patients with heart failure with ejection fraction >40% - the results of HF-POL, the first Polish registry of Heart Failure Association
22 May 2023
thumbnail
Congress Presentation
Efficacy of dapagliflozin according to heart rate in patients with heart failure: a patient-level pooled analysis of DAPA-HF and DELIVER
22 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources